• UIJ Home
• In Press
• Authors
• Current Issue
• Past Issues
• Email Alerts
• Search the Journal

UIJ - A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer – CA180-227

Published on June 01, 2009

Article Keywords: UroToday International Journal, UroToday International, A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer – CA180-227

Clinical Research Study Now Enrolling Subjects with Castration-Resistant Prostate Cancer A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer – CA180-227 Inclusion/Exclusion Criteria Confirmed prostate cancer Progressing disease despite castration status (i.e., castration-resistant) Metastatic disease requiring chemotherapy No prior chemotherapy (except for estramustine) or current anti-androgen therapy No currently active CNS disease and/or secondary malignancy No pleural or pericardial effusion For more information, please see www.clinicaltrials.gov and search under CT Identifier NCT00744497 View Bulletin in PDF Format

 

< Prev		Next >

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1944-5784 Privacy Policy | © 2009 UroToday ® All Rights Reserved